Ost-müük Ionis Pharmaceuticals, Inc. - IONS CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.34 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 34.76 |
Avatud* | 35 |
Aastane muutus* | -1.82% |
Päeva ulatus* | 35 - 35.66 |
52 nädala ulatus | 31.46-48.82 |
Keskmine maht (10 päeva) | 1.09M |
Keskmine maht (3 kuud) | 19.95M |
Turukapitalisatsioon | 4.99B |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 142.95M |
Tulu | 587.37M |
EPS | -1.90 |
Dividendid (% kasumist) | N/A |
Beeta | 0.54 |
Järgmine tuluaruande kuupäev | May 2, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 35.57 | 1.03 | 2.98% | 34.54 | 35.76 | 34.54 |
Mar 30, 2023 | 34.76 | -0.55 | -1.56% | 35.31 | 35.61 | 33.53 |
Mar 29, 2023 | 35.33 | 0.61 | 1.76% | 34.72 | 35.47 | 33.40 |
Mar 28, 2023 | 34.27 | 1.69 | 5.19% | 32.58 | 34.33 | 32.58 |
Mar 27, 2023 | 33.67 | -0.24 | -0.71% | 33.91 | 34.30 | 33.46 |
Mar 24, 2023 | 33.91 | 0.61 | 1.83% | 33.30 | 34.13 | 32.65 |
Mar 23, 2023 | 33.61 | -1.58 | -4.49% | 35.19 | 35.41 | 33.28 |
Mar 22, 2023 | 35.16 | 0.14 | 0.40% | 35.02 | 35.57 | 34.55 |
Mar 21, 2023 | 35.47 | 0.53 | 1.52% | 34.94 | 35.75 | 34.67 |
Mar 20, 2023 | 35.45 | -0.31 | -0.87% | 35.76 | 36.04 | 35.03 |
Mar 17, 2023 | 35.04 | 0.77 | 2.25% | 34.27 | 35.20 | 33.70 |
Mar 16, 2023 | 34.86 | 1.50 | 4.50% | 33.36 | 35.00 | 33.36 |
Mar 15, 2023 | 34.15 | 0.99 | 2.99% | 33.16 | 34.18 | 32.63 |
Mar 14, 2023 | 33.74 | 0.43 | 1.29% | 33.31 | 33.88 | 32.39 |
Mar 13, 2023 | 33.50 | 0.15 | 0.45% | 33.35 | 34.65 | 33.35 |
Mar 10, 2023 | 33.91 | 0.05 | 0.15% | 33.86 | 34.75 | 33.52 |
Mar 9, 2023 | 34.62 | -0.80 | -2.26% | 35.42 | 35.72 | 34.28 |
Mar 8, 2023 | 35.62 | 0.12 | 0.34% | 35.50 | 35.83 | 35.15 |
Mar 7, 2023 | 35.65 | -0.22 | -0.61% | 35.87 | 36.14 | 35.49 |
Mar 6, 2023 | 36.12 | -0.10 | -0.28% | 36.22 | 36.63 | 35.81 |
Ionis Pharmaceuticals, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Tuesday, April 4, 2023 | ||
Kellaaeg (UTC) (UTC) 14:45 | Riik US
| Sündmus Ionis Pharmaceuticals Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Ionis Pharmaceuticals Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual)Forecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Tulu | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Kulud, Kokku | 14.116 | 10.842 | 11.947 | 4.384 | 1.82 |
Brutokasum | 573.251 | 799.614 | 717.317 | 1118.21 | 597.854 |
Kogu tegevuskulu | 997.558 | 849.269 | 901.346 | 822.912 | 661.046 |
Müük/Üldine/admin kulud, kokku | 150.295 | 170.947 | 332.222 | 286.644 | 244.622 |
Uuringud ja arendus | 833.147 | 634.953 | 526.877 | 465.688 | 414.604 |
Ootamatud kulutused (tulu) | 32.527 | 30.3 | 66.196 | 0 | |
Tulud majandustegevusest | -410.191 | -38.813 | -172.082 | 299.687 | -61.372 |
Intressitulud (kulu), muud tulud, neto | 9.876 | 10.798 | 37.592 | 39.765 | -14.602 |
Muud, neto | -7.274 | -1.133 | -0.062 | -0.686 | -0.182 |
Netotulu enne makse | -257.985 | -29.148 | -134.552 | 338.766 | -76.156 |
Netotulu pärast makse | -269.722 | -28.597 | -479.743 | 287.259 | -117.115 |
Vähemuse intress | 0 | 0 | 35.48 | -9.116 | 58.756 |
Netotulu enne erikulusid | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Netotulu | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Arvestatav tulu, v a erikulud | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Arvestatav tulu, koos erikuludega | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Jaotuse korrigeerimine | 0 | ||||
Jaotamisele kuuluv netotulu | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Keskmine jaotamisele kuuluv aktsia kohta | 141.848 | 141.021 | 139.612 | 153.164 | 134.056 |
Jaotatav EPS, v a erakorralised kulud | -1.90149 | -0.20279 | -3.18213 | 1.81598 | -0.43533 |
Jaotamisele kuuluv normaal-EPS | -2.58703 | -0.05286 | -3.04106 | 2.18246 | -0.43533 |
Erakorralised kulud kokku | 332.1 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Tulu | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Kulud, Kokku | 3.686 | 1.515 | 4.745 | 4.17 | 2.226 |
Brutokasum | 148.203 | 158.252 | 129.046 | 137.749 | 437.78 |
Kogu tegevuskulu | 359.908 | 218.921 | 219.305 | 199.423 | 219.401 |
Müük/Üldine/admin kulud, kokku | 47.95 | 34.416 | 33.802 | 34.127 | 37.6 |
Uuringud ja arendus | 308.272 | 182.99 | 180.758 | 161.126 | 179.575 |
Tulud majandustegevusest | -208.019 | -59.154 | -85.514 | -57.504 | 220.605 |
Intressitulud (kulu), muud tulud, neto | 13.436 | 7.732 | -5.064 | -6.754 | 4.788 |
Muud, neto | 0.649 | 4.713 | -12.297 | 0.187 | -0.477 |
Netotulu enne makse | -44.33 | -46.709 | -102.875 | -64.071 | 224.916 |
Netotulu pärast makse | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Vähemuse intress | 0 | 0 | |||
Netotulu enne erikulusid | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Netotulu | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Arvestatav tulu, v a erikulud | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Arvestatav tulu, koos erikuludega | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Jaotamisele kuuluv netotulu | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Keskmine jaotamisele kuuluv aktsia kohta | 142.046 | 141.95 | 141.794 | 141.599 | 141.21 |
Jaotatav EPS, v a erakorralised kulud | -0.36911 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -1.05369 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Ootamatud kulutused (tulu) | 0 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 2345.05 | 2130.71 | 2720.6 | 2207.89 | 1168.73 |
Raha ja lühiajalised investeeringud | 2114.97 | 1892.38 | 2499.54 | 2084.07 | 1022.72 |
Raha ja ekvivalendid | 869.191 | 397.664 | 683.287 | 278.82 | 129.63 |
Lühiajalised investeeringud | 1245.78 | 1494.71 | 1816.26 | 1805.25 | 893.085 |
Laekumata arved, neto | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Accounts Receivable - Trade, Net | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Total Inventory | 24.806 | 21.965 | 18.18 | 8.582 | 9.982 |
Other Current Assets, Total | 143.374 | 140.163 | 139.839 | 102.473 | 73.082 |
Total Assets | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Property/Plant/Equipment, Total - Net | 196.069 | 181.077 | 166.251 | 132.16 | 121.907 |
Property/Plant/Equipment, Total - Gross | 298.722 | 240.264 | 193.634 | 209.583 | |
Accumulated Depreciation, Total | -102.653 | -74.013 | -61.474 | -87.676 | |
Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | 22.004 |
Other Long Term Assets, Total | 41.567 | 50.034 | 320.59 | 303.706 | 10.129 |
Total Current Liabilities | 240.55 | 598.898 | 273.005 | 280.294 | 243.612 |
Accounts Payable | 11.904 | 17.199 | 16.067 | 28.66 | 24.886 |
Accrued Expenses | 129.97 | 155.889 | 106.152 | 77.629 | 91.769 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.926 | 316.11 | 13.749 | 1.621 | |
Other Current Liabilities, Total | 97.75 | 109.7 | 150.786 | 160.256 | 125.336 |
Total Liabilities | 1839.95 | 1646.47 | 1762.02 | 1619.7 | 1041.76 |
Total Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 371.379 | 424.046 | 505.26 | 567.359 | 108.026 |
Total Equity | 771.737 | 743.282 | 1471.09 | 1048.08 | 281.013 |
Common Stock | 0.141 | 0.14 | 0.14 | 0.138 | 0.125 |
Additional Paid-In Capital | 1964.17 | 1895.52 | 2203.78 | 2047.25 | 1553.68 |
Retained Earnings (Accumulated Deficit) | -1159.9 | -1131.31 | -707.534 | -967.293 | -1241.03 |
Other Equity, Total | -32.668 | -21.071 | -25.29 | -32.016 | -31.759 |
Total Liabilities & Shareholders’ Equity | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Total Common Shares Outstanding | 141.21 | 140.366 | 140.34 | 137.929 | 124.976 |
Minority Interest | 213.453 | 139.081 | 84.267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 2253.12 | 2345.05 | 2155.74 | 2238.42 | 1989.42 |
Raha ja lühiajalised investeeringud | 2052.39 | 2114.97 | 1987.1 | 2059.27 | 1819.99 |
Raha ja ekvivalendid | 542.513 | 869.191 | 632.953 | 565.119 | 414.155 |
Lühiajalised investeeringud | 1509.88 | 1245.78 | 1354.15 | 1494.15 | 1405.84 |
Laekumata arved, neto | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Accounts Receivable - Trade, Net | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Total Inventory | 24.032 | 24.806 | 22.93 | 24.099 | 22.199 |
Other Current Assets, Total | 150.577 | 143.374 | 136.643 | 131.045 | 123.827 |
Total Assets | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Property/Plant/Equipment, Total - Net | 177.724 | 196.069 | 180.144 | 179.316 | 180.413 |
Intangibles, Net | 29.295 | 29.005 | 30.038 | 29.373 | 28.795 |
Other Long Term Assets, Total | 58.949 | 41.567 | 48.971 | 49.962 | 49.925 |
Total Current Liabilities | 228.45 | 240.55 | 279.778 | 293.825 | 295.105 |
Accounts Payable | 16.125 | 11.904 | 8.357 | 14.658 | 9.506 |
Accrued Expenses | 115.781 | 129.97 | 108.001 | 105.372 | 108.029 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.206 | 0.926 | 65.045 | 69.848 | 69.504 |
Other Current Liabilities, Total | 92.338 | 97.75 | 98.375 | 103.947 | 108.066 |
Total Liabilities | 1809.52 | 1839.95 | 1884.36 | 1914.4 | 1567.99 |
Total Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Other Liabilities, Total | 333.138 | 371.379 | 362.887 | 379.874 | 401.966 |
Total Equity | 709.574 | 771.737 | 530.536 | 582.674 | 680.564 |
Common Stock | 0.142 | 0.141 | 0.141 | 0.141 | 0.141 |
Additional Paid-In Capital | 1983.08 | 1964.17 | 1942.35 | 1910.38 | 1925.8 |
Retained Earnings (Accumulated Deficit) | -1225.07 | -1159.9 | -1384.52 | -1302.05 | -1221.18 |
Other Equity, Total | -48.578 | -32.668 | -27.437 | -25.796 | -24.203 |
Total Liabilities & Shareholders’ Equity | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Total Common Shares Outstanding | 141.753 | 141.21 | 141.184 | 141.022 | 140.924 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -28.597 | -479.743 | 287.259 | 214.985 | -10.783 |
Raha majandustegevusest | 30.799 | 35.892 | 345.627 | 602.906 | 174.149 |
Raha majandustegevusest | 15.487 | 13.365 | 12.54 | 10.706 | 6.708 |
Amortization | 2.352 | 2.064 | 1.912 | 1.822 | 1.641 |
Deferred Taxes | 0 | 341.729 | 0.911 | -290.516 | 0 |
Mittelikviidsed varad | 155.375 | 232.032 | 211.806 | 166.484 | 139.539 |
Makstud intressid | 4.778 | 6.247 | 9.87 | 9.592 | 8.035 |
Muutused tööjõus | -113.818 | -73.555 | -168.801 | 499.425 | 37.044 |
Tulu investeeringutelt | 194.906 | 274.477 | -41.274 | -929.563 | -358.291 |
Kapitalikulutused | -11.955 | -35.12 | -30.905 | -13.608 | -34.764 |
Muud rahavood investeeringutelt, kokku | 206.861 | 309.597 | -10.369 | -915.955 | -323.527 |
Rahavood investeeringutelt | 245.933 | -596.609 | 100.021 | 475.865 | 229.087 |
Rahavoogudesse investeerimine | -168.954 | -558.097 | -138.354 | 0 | 47.963 |
Aktsiate emiteerimine (tagasiost), neto | 101.317 | -38.512 | 141.375 | 475.865 | 205.106 |
Laenu väljastamine (kustutamine), neto | 313.57 | 0 | 97 | 0 | -23.982 |
Rahaline kogumuutus | 471.527 | -285.623 | 404.467 | 149.19 | 44.945 |
Cash Taxes Paid | 0.038 | 25.855 | 9.041 | 0 | |
Muutused valuutakursside kõikumisest | -0.111 | 0.617 | 0.093 | -0.018 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.165 | -28.597 | -253.21 | -170.744 | -89.869 |
Cash From Operating Activities | -31.65 | 30.799 | -172.888 | -117.314 | -54.662 |
Cash From Operating Activities | 3.701 | 15.487 | 11.665 | 7.951 | 3.917 |
Amortization | 0.592 | 2.352 | 1.74 | 1.137 | 0.544 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Non-Cash Items | 32.983 | 155.375 | 125.535 | 88.261 | 43.346 |
Cash Taxes Paid | 0.002 | 0.038 | 0.003 | 0.002 | |
Cash Interest Paid | 0.594 | 4.778 | 3.527 | 2.866 | 0.594 |
Changes in Working Capital | -3.761 | -113.818 | -58.618 | -43.919 | -12.6 |
Cash From Investing Activities | -287.549 | 194.906 | 99.797 | -22.174 | 78.856 |
Capital Expenditures | -2.705 | -11.955 | -9.453 | -6.13 | -1.772 |
Other Investing Cash Flow Items, Total | -284.844 | 206.861 | 109.25 | -16.044 | 80.628 |
Cash From Financing Activities | -7.325 | 245.933 | 308.423 | 306.965 | -7.577 |
Financing Cash Flow Items | -9.173 | -168.954 | -168.43 | -167.966 | -15.337 |
Issuance (Retirement) of Stock, Net | 1.848 | 101.317 | 101.316 | 99.394 | 7.76 |
Foreign Exchange Effects | -0.154 | -0.111 | -0.043 | -0.022 | -0.126 |
Net Change in Cash | -326.678 | 471.527 | 235.289 | 167.455 | 16.491 |
Issuance (Retirement) of Debt, Net | 313.57 | 375.537 | 375.537 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.9052 | 21307519 | 16360 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4574 | 13519789 | 736550 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 8.1692 | 11678259 | 521564 | 2022-12-31 | MED |
Bellevue Asset Management AG | Investment Advisor | 6.8161 | 9743900 | 280500 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.986 | 7127720 | 135266 | 2022-12-31 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7954 | 5425642 | -348250 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9511 | 4218729 | 457774 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.9049 | 4152607 | -508999 | 2022-12-31 | LOW |
Tweedy, Browne Company LLC | Investment Advisor | 2.4771 | 3541136 | 818148 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 1.8702 | 2673538 | -1039569 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.408 | 2012723 | 111580 | 2022-12-31 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.3946 | 1993600 | 1224700 | 2022-12-31 | LOW |
Camber Capital Management LP | Hedge Fund | 1.3466 | 1925000 | 0 | 2022-12-31 | MED |
First Trust Advisors L.P. | Investment Advisor | 1.2458 | 1780933 | -296327 | 2022-12-31 | LOW |
Macquarie Investment Management | Investment Advisor | 1.0435 | 1491687 | 657646 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.907 | 1296647 | 465428 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8788 | 1256268 | 53922 | 2022-12-31 | LOW |
Deep Track Capital LP | Hedge Fund | 0.8435 | 1205773 | 1205773 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.8246 | 1178814 | 311100 | 2022-12-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7966 | 1138714 | 15634 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
Ettevõttest Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. tegeleb ribonukleiinhappe (RNA) sihtotstarbeliste ravimite avastamise ja arendamisega. Ettevõte keskendub peamiselt meie kardiovaskulaarsele ja neuroloogilisele frantsiisile. Tema toodete hulka kuuluvad SPINRAZA, TEGSEDI ja WAYLIVRA. SPINRAZA on mõeldud igas vanuses spinaalse lihasatroofia (SMA) patsientide raviks, mis on progresseeruv, invaliidistav ja sageli surmaga lõppev geneetiline haigus. TEGSEDI on mõeldud päriliku transstüreetiini (TTR), amüloidoosi (hATTR) põhjustatud polüneuropaatia patsientide raviks, mis on invaliidistav, progresseeruv ja surmaga lõppev haigus. WAYLIVRA on antiseptiline ravim, mis on näidustatud täiskasvanud patsientidel dieedi lisana. Ettevõttel on üle kuue ravimi III faasi uuringutes kaheksal näidustusel, mille hulka kuuluvad Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) ja Tofersen (SOD1). Tema väljatöötamisel olevate kardiovaskulaarsete ravimite hulka kuuluvad Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen ja IONIS-AGT-LRx.
Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com